learn GT20029
research compound made to degrade androgen receptors in scalp
Search
forLearn
1 / 1 resultsResearch
5 / 1000+ resultsresearch Proteolysis-Targeting Chimera (PROTAC): Current Applications And Future Directions
PROTACs offer new ways to treat hard-to-target diseases, with promising drugs for cancer in advanced trials.
research Enriching Proteolysis Targeting Chimeras with a Second Modality: When Two Are Better Than One
Adding a second method to PROTACs could improve cancer treatment.
research Protacs: A Novel Strategy For Cancer Drug Discovery And Development
PROTAC technology shows promise for cancer treatment but needs more effective E3 ligase recruiters.
research Protac Degraders of Androgen Receptor-Integrated Dissolving Microneedles for Androgenetic Alopecia and Recrudescence Treatment via Single Topical Administration
A new hair loss treatment using dissolving microneedles was found to speed up hair growth and was more effective than daily use of common hair growth drugs.
research Advancements in Treatment Strategies for Androgenetic Alopecia: Novel Therapies and Future Perspectives
New treatments for androgenetic alopecia show promise but need more research for validation.
Community Join
5 / 70 resultscommunity Pyrilutamide binding affinity is similar to RU
Comparing the effectiveness of RU58841, Pyrilutamide and CB-03-01 as treatments for hair loss, with people discussing different aspects such as binding affinity, time of inhibition, safety data and cost.
community More great news about SCUBE3... this could be it!
SCUBE3 is a potential hair loss treatment that people are hopeful about. It may provide a solution without the side effects of finasteride.
community Kintor has announced the results for their human Phase I trials of GT20029
The conversation discusses the potential of a new hair loss treatment, GT20029, which may prevent hair loss by destroying androgen receptors on the scalp. Users express hope for the treatment's success and speculate on its usage routine, effectiveness, and possible side effects.
community Kintor Pharma Announces Positive Top-line U.S. Phase I Trial Results of GT20029, the World’s First Topical Use PROTAC Compound
The conversation discusses positive initial trial results for GT20029, a topical compound for hair loss that degrades androgen receptors, potentially requiring only weekly application. Participants express hope for this treatment to be more effective and convenient than current options like Minoxidil, Finasteride, and RU58841.
community Anageninc no longer sell KX-826 (Pyrilutamide) due to receiving a cease and desist letter from Kintor :(
Hair loss treatments discussed include Minoxidil, Finasteride, and RU58841. Anageninc stopped selling KX-826 (Pyrilutamide) due to a cease and desist letter from Kintor, but this may indicate promising study results and a potential 2024 release.